Literature DB >> 29286425

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag.

Genta Ito1, Taisuke Tomita2.   

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) have been shown to be linked with familial Parkinson's disease (FPD). Since abnormal activation of the kinase activity of LRRK2 has been implicated in the pathogenesis of PD, it is essential to establish a method to evaluate the physiological levels of the kinase activity of LRRK2. Recent studies revealed that LRRK2 phosphorylates members of the Rab GTPase family, including Rab10, under physiological conditions. Although the phosphorylation of endogenous Rab10 by LRRK2 in cultured cells could be detected by mass spectrometry, it has been difficult to detect it by immunoblotting due to the poor sensitivity of currently available phosphorylation-specific antibodies for Rab10. Here, we describe a simple method of detecting the endogenous levels of Rab10 phosphorylation by LRRK2 based on immunoblotting utilizing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with a phosphate-binding tag (P-tag), which is N-(5-(2-aminoethylcarbamoyl)pyridin-2-ylmetyl)-N,N',N'-tris(pyridin-2-yl-methyl)-1,3-diaminopropan-2-ol. The present protocol not only provides an example of the methodology utilizing the P-tag but also enables the assessment of how mutations as well as inhibitor treatment/administration or any other factors alter the downstream signaling of LRRK2 in cells and tissues.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29286425      PMCID: PMC5755567          DOI: 10.3791/56688

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  22 in total

1.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

2.  Immunoblotting and Immunodetection.

Authors:  Duojiao Ni; Peng Xu; Sean Gallagher
Journal:  Curr Protoc Mol Biol       Date:  2016-04-01

Review 3.  The clinical symptoms of Parkinson's disease.

Authors:  Sigurlaug Sveinbjornsdottir
Journal:  J Neurochem       Date:  2016-07-11       Impact factor: 5.372

4.  MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.

Authors:  Matthew J Fell; Christian Mirescu; Kallol Basu; Boonlert Cheewatrakoolpong; Duane E DeMong; J Michael Ellis; Lynn A Hyde; Yinghui Lin; Carrie G Markgraf; Hong Mei; Michael Miller; Frederique M Poulet; Jack D Scott; Michelle D Smith; Zhizhang Yin; Xiaoping Zhou; Eric M Parker; Matthew E Kennedy; John A Morrow
Journal:  J Pharmacol Exp Ther       Date:  2015-09-25       Impact factor: 4.030

Review 5.  Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Authors:  Dena G Hernandez; Xylena Reed; Andrew B Singleton
Journal:  J Neurochem       Date:  2016-04-18       Impact factor: 5.372

6.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.

Authors:  Wataru Satake; Yuko Nakabayashi; Ikuko Mizuta; Yushi Hirota; Chiyomi Ito; Michiaki Kubo; Takahisa Kawaguchi; Tatsuhiko Tsunoda; Masahiko Watanabe; Atsushi Takeda; Hiroyuki Tomiyama; Kenji Nakashima; Kazuko Hasegawa; Fumiya Obata; Takeo Yoshikawa; Hideshi Kawakami; Saburo Sakoda; Mitsutoshi Yamamoto; Nobutaka Hattori; Miho Murata; Yusuke Nakamura; Tatsushi Toda
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

7.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

8.  Regulation of LRRK2 expression points to a functional role in human monocyte maturation.

Authors:  Jonathan Thévenet; Rosanna Pescini Gobert; Robertus Hooft van Huijsduijnen; Christoph Wiessner; Yves Jean Sagot
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

9.  LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease.

Authors:  Ahmed Bouhouche; Houyam Tibar; Rafiqua Ben El Haj; Khalil El Bayad; Rachid Razine; Sanaa Tazrout; Asmae Skalli; Naima Bouslam; Loubna Elouardi; Ali Benomar; Mohammed Yahyaoui; Wafa Regragui
Journal:  Parkinsons Dis       Date:  2017-03-30

10.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.

Authors:  Javier Simón-Sánchez; Claudia Schulte; Jose M Bras; Manu Sharma; J Raphael Gibbs; Daniela Berg; Coro Paisan-Ruiz; Peter Lichtner; Sonja W Scholz; Dena G Hernandez; Rejko Krüger; Monica Federoff; Christine Klein; Alison Goate; Joel Perlmutter; Michael Bonin; Michael A Nalls; Thomas Illig; Christian Gieger; Henry Houlden; Michael Steffens; Michael S Okun; Brad A Racette; Mark R Cookson; Kelly D Foote; Hubert H Fernandez; Bryan J Traynor; Stefan Schreiber; Sampath Arepalli; Ryan Zonozi; Katrina Gwinn; Marcel van der Brug; Grisel Lopez; Stephen J Chanock; Arthur Schatzkin; Yikyung Park; Albert Hollenbeck; Jianjun Gao; Xuemei Huang; Nick W Wood; Delia Lorenz; Günther Deuschl; Honglei Chen; Olaf Riess; John A Hardy; Andrew B Singleton; Thomas Gasser
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

View more
  1 in total

1.  The atypical Rab GTPase associated with Parkinson's disease, Rab29, is localized to membranes.

Authors:  Yuki Nagai-Ito; Lejia Xu; Kyohei Ito; Yotaro Kajihara; Genta Ito; Taisuke Tomita
Journal:  J Biol Chem       Date:  2022-09-15       Impact factor: 5.486

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.